Atypical B cells and impaired SARS-CoV-2 neutralisation following booster vaccination in the elderly
Isabella A.T.M. Ferreira, Colin Y.C. Lee, William Foster, Adam Abdullahi, Zewen Kelvin Tuong, Benjamin J Stewart, John R. Ferdinand, Stephane Guillaume, Martin O.P. Potts, Marianne Perera, Benjamin A. Krishna, Ana P. Alonso, Mia Cabantous, Steven A. Kemp, Lourdes Ceron-Gutierrez, Soraya Ebrahimi, The CITIID-NIHR BioResource COVID-19 Collaboration, Paul Lyons, Kenneth GC Smith, John Bradley, Dami A. Collier, Sarah A. Teichmann, Laura E. McCoy, Paul A. MacAry, Rainer Doffinger, Mark R. Wills, Michelle Linterman, Menna R. Clatworthy, View ORCID ProfileRavindra K. Gupta
doi: https://doi.org/10.1101/2022.10.13.22281024
Isabella A.T.M. Ferreira
1Cambridge Institute of Therapeutic Immunology and Infectious Disease (CITIID), Cambridge, UK
2Department of Medicine, University of Cambridge, Cambridge, UK
Colin Y.C. Lee
3Molecular Immunity Unit, Department of Medicine, Medical Research Council Laboratory of Molecular Biology, University of Cambridge, Cambridge, UK
4Wellcome Sanger Institute, Cambridge, UK
William Foster
5Lymphocyte Signalling and Development, Babraham Institute, Babraham Research Campus, Cambridge, UK
Adam Abdullahi
1Cambridge Institute of Therapeutic Immunology and Infectious Disease (CITIID), Cambridge, UK
2Department of Medicine, University of Cambridge, Cambridge, UK
Zewen Kelvin Tuong
3Molecular Immunity Unit, Department of Medicine, Medical Research Council Laboratory of Molecular Biology, University of Cambridge, Cambridge, UK
4Wellcome Sanger Institute, Cambridge, UK
Benjamin J Stewart
3Molecular Immunity Unit, Department of Medicine, Medical Research Council Laboratory of Molecular Biology, University of Cambridge, Cambridge, UK
4Wellcome Sanger Institute, Cambridge, UK
John R. Ferdinand
3Molecular Immunity Unit, Department of Medicine, Medical Research Council Laboratory of Molecular Biology, University of Cambridge, Cambridge, UK
Stephane Guillaume
5Lymphocyte Signalling and Development, Babraham Institute, Babraham Research Campus, Cambridge, UK
Martin O.P. Potts
1Cambridge Institute of Therapeutic Immunology and Infectious Disease (CITIID), Cambridge, UK
2Department of Medicine, University of Cambridge, Cambridge, UK
Marianne Perera
1Cambridge Institute of Therapeutic Immunology and Infectious Disease (CITIID), Cambridge, UK
2Department of Medicine, University of Cambridge, Cambridge, UK
Benjamin A. Krishna
1Cambridge Institute of Therapeutic Immunology and Infectious Disease (CITIID), Cambridge, UK
2Department of Medicine, University of Cambridge, Cambridge, UK
Ana P. Alonso
3Molecular Immunity Unit, Department of Medicine, Medical Research Council Laboratory of Molecular Biology, University of Cambridge, Cambridge, UK
Mia Cabantous
3Molecular Immunity Unit, Department of Medicine, Medical Research Council Laboratory of Molecular Biology, University of Cambridge, Cambridge, UK
Steven A. Kemp
1Cambridge Institute of Therapeutic Immunology and Infectious Disease (CITIID), Cambridge, UK
2Department of Medicine, University of Cambridge, Cambridge, UK
Lourdes Ceron-Gutierrez
6Department of Clinical Biochemistry and Immunology, Cambridge University Hospital NHS Trust, Cambridge, UK
Soraya Ebrahimi
6Department of Clinical Biochemistry and Immunology, Cambridge University Hospital NHS Trust, Cambridge, UK
Paul Lyons
1Cambridge Institute of Therapeutic Immunology and Infectious Disease (CITIID), Cambridge, UK
2Department of Medicine, University of Cambridge, Cambridge, UK
Kenneth GC Smith
1Cambridge Institute of Therapeutic Immunology and Infectious Disease (CITIID), Cambridge, UK
2Department of Medicine, University of Cambridge, Cambridge, UK
John Bradley
1Cambridge Institute of Therapeutic Immunology and Infectious Disease (CITIID), Cambridge, UK
2Department of Medicine, University of Cambridge, Cambridge, UK
Dami A. Collier
1Cambridge Institute of Therapeutic Immunology and Infectious Disease (CITIID), Cambridge, UK
2Department of Medicine, University of Cambridge, Cambridge, UK
Sarah A. Teichmann
4Wellcome Sanger Institute, Cambridge, UK
Laura E. McCoy
7Division of infection and immunity, UCL, London, UK
Paul A. MacAry
8National University of Singapore, Singapore
Rainer Doffinger
6Department of Clinical Biochemistry and Immunology, Cambridge University Hospital NHS Trust, Cambridge, UK
Mark R. Wills
1Cambridge Institute of Therapeutic Immunology and Infectious Disease (CITIID), Cambridge, UK
2Department of Medicine, University of Cambridge, Cambridge, UK
Michelle Linterman
5Lymphocyte Signalling and Development, Babraham Institute, Babraham Research Campus, Cambridge, UK
Menna R. Clatworthy
1Cambridge Institute of Therapeutic Immunology and Infectious Disease (CITIID), Cambridge, UK
3Molecular Immunity Unit, Department of Medicine, Medical Research Council Laboratory of Molecular Biology, University of Cambridge, Cambridge, UK
4Wellcome Sanger Institute, Cambridge, UK
Ravindra K. Gupta
1Cambridge Institute of Therapeutic Immunology and Infectious Disease (CITIID), Cambridge, UK
2Department of Medicine, University of Cambridge, Cambridge, UK
![Loading Loading](https://www.medrxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif)
Article usage
Posted October 13, 2022.
Atypical B cells and impaired SARS-CoV-2 neutralisation following booster vaccination in the elderly
Isabella A.T.M. Ferreira, Colin Y.C. Lee, William Foster, Adam Abdullahi, Zewen Kelvin Tuong, Benjamin J Stewart, John R. Ferdinand, Stephane Guillaume, Martin O.P. Potts, Marianne Perera, Benjamin A. Krishna, Ana P. Alonso, Mia Cabantous, Steven A. Kemp, Lourdes Ceron-Gutierrez, Soraya Ebrahimi, The CITIID-NIHR BioResource COVID-19 Collaboration, Paul Lyons, Kenneth GC Smith, John Bradley, Dami A. Collier, Sarah A. Teichmann, Laura E. McCoy, Paul A. MacAry, Rainer Doffinger, Mark R. Wills, Michelle Linterman, Menna R. Clatworthy, Ravindra K. Gupta
medRxiv 2022.10.13.22281024; doi: https://doi.org/10.1101/2022.10.13.22281024
Atypical B cells and impaired SARS-CoV-2 neutralisation following booster vaccination in the elderly
Isabella A.T.M. Ferreira, Colin Y.C. Lee, William Foster, Adam Abdullahi, Zewen Kelvin Tuong, Benjamin J Stewart, John R. Ferdinand, Stephane Guillaume, Martin O.P. Potts, Marianne Perera, Benjamin A. Krishna, Ana P. Alonso, Mia Cabantous, Steven A. Kemp, Lourdes Ceron-Gutierrez, Soraya Ebrahimi, The CITIID-NIHR BioResource COVID-19 Collaboration, Paul Lyons, Kenneth GC Smith, John Bradley, Dami A. Collier, Sarah A. Teichmann, Laura E. McCoy, Paul A. MacAry, Rainer Doffinger, Mark R. Wills, Michelle Linterman, Menna R. Clatworthy, Ravindra K. Gupta
medRxiv 2022.10.13.22281024; doi: https://doi.org/10.1101/2022.10.13.22281024
Subject Area
Subject Areas
- Addiction Medicine (336)
- Allergy and Immunology (664)
- Anesthesia (178)
- Cardiovascular Medicine (2599)
- Dermatology (218)
- Emergency Medicine (391)
- Epidemiology (12134)
- Forensic Medicine (10)
- Gastroenterology (752)
- Genetic and Genomic Medicine (4028)
- Geriatric Medicine (379)
- Health Economics (670)
- Health Informatics (2605)
- Health Policy (994)
- Hematology (358)
- HIV/AIDS (831)
- Medical Education (397)
- Medical Ethics (109)
- Nephrology (426)
- Neurology (3797)
- Nursing (208)
- Nutrition (563)
- Oncology (1989)
- Ophthalmology (576)
- Orthopedics (235)
- Otolaryngology (303)
- Pain Medicine (249)
- Palliative Medicine (72)
- Pathology (470)
- Pediatrics (1098)
- Primary Care Research (443)
- Public and Global Health (6469)
- Radiology and Imaging (1379)
- Respiratory Medicine (866)
- Rheumatology (395)
- Sports Medicine (337)
- Surgery (438)
- Toxicology (51)
- Transplantation (185)
- Urology (165)